Seek Returns logo

THC vs. VTRS: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at THC and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolTHCVTRS
Company NameTenet Healthcare CorporationViatris Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Providers & ServicesPharmaceuticals
Market Capitalization16.07 billion USD12.42 billion USD
ExchangeNYSENasdaqGS
Listing DateMarch 17, 1980March 17, 1980
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of THC and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

THC vs. VTRS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolTHCVTRS
5-Day Price Return5.56%-0.37%
13-Week Price Return8.76%21.58%
26-Week Price Return36.21%-1.39%
52-Week Price Return16.49%-9.97%
Month-to-Date Return12.81%21.85%
Year-to-Date Return44.13%-14.46%
10-Day Avg. Volume0.97M11.82M
3-Month Avg. Volume1.56M12.30M
3-Month Volatility36.93%32.62%
Beta1.520.89

Profitability

Return on Equity (TTM)

THC

37.25%

Health Care Providers & Services Industry

Max
26.03%
Q3
13.74%
Median
8.26%
Q1
4.13%
Min
-3.62%

THC’s Return on Equity of 37.25% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

VTRS

-19.92%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

THC vs. VTRS: A comparison of their Return on Equity (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

THC

7.17%

Health Care Providers & Services Industry

Max
12.40%
Q3
5.93%
Median
1.96%
Q1
0.93%
Min
-6.10%

A Net Profit Margin of 7.17% places THC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.

VTRS

-24.57%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

THC vs. VTRS: A comparison of their Net Profit Margin (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

THC

17.77%

Health Care Providers & Services Industry

Max
19.05%
Q3
10.21%
Median
4.22%
Q1
1.98%
Min
-4.27%

An Operating Profit Margin of 17.77% places THC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

VTRS

-26.54%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

THC vs. VTRS: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolTHCVTRS
Return on Equity (TTM)37.25%-19.92%
Return on Assets (TTM)5.11%-8.50%
Net Profit Margin (TTM)7.17%-24.57%
Operating Profit Margin (TTM)17.77%-26.54%
Gross Profit Margin (TTM)82.36%40.15%

Financial Strength

Current Ratio (MRQ)

THC

1.71

Health Care Providers & Services Industry

Max
2.01
Q3
1.49
Median
1.30
Q1
0.94
Min
0.17

THC’s Current Ratio of 1.71 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

VTRS

1.37

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

THC vs. VTRS: A comparison of their Current Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

THC

3.51

Health Care Providers & Services Industry

Max
2.17
Q3
1.18
Median
0.74
Q1
0.45
Min
0.00

With a Debt-to-Equity Ratio of 3.51, THC operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

VTRS

0.82

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

VTRS’s Debt-to-Equity Ratio of 0.82 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

THC vs. VTRS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

THC

10.27

Health Care Providers & Services Industry

Max
14.47
Q3
7.15
Median
5.45
Q1
2.04
Min
-4.44

THC’s Interest Coverage Ratio of 10.27 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

VTRS

-0.13

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

THC vs. VTRS: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolTHCVTRS
Current Ratio (MRQ)1.711.37
Quick Ratio (MRQ)1.540.65
Debt-to-Equity Ratio (MRQ)3.510.82
Interest Coverage Ratio (TTM)10.27-0.13

Growth

Revenue Growth

THC vs. VTRS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

THC vs. VTRS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

THC

0.00%

Health Care Providers & Services Industry

Max
5.38%
Q3
2.22%
Median
0.55%
Q1
0.00%
Min
0.00%

THC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

VTRS

4.58%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

With a Dividend Yield of 4.58%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

THC vs. VTRS: A comparison of their Dividend Yield (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

THC

0.00%

Health Care Providers & Services Industry

Max
186.69%
Q3
74.82%
Median
26.76%
Q1
0.00%
Min
0.00%

THC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

VTRS

137.04%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

THC vs. VTRS: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolTHCVTRS
Dividend Yield (TTM)0.00%4.58%
Dividend Payout Ratio (TTM)0.00%137.04%

Valuation

Price-to-Earnings Ratio (TTM)

THC

10.79

Health Care Providers & Services Industry

Max
55.89
Q3
30.85
Median
21.17
Q1
12.63
Min
0.00

In the lower quartile for the Health Care Providers & Services industry, THC’s P/E Ratio of 10.79 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

VTRS

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for VTRS is currently unavailable.

THC vs. VTRS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

THC

0.77

Health Care Providers & Services Industry

Max
3.10
Q3
1.74
Median
0.67
Q1
0.24
Min
0.00

THC’s P/S Ratio of 0.77 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

VTRS

0.88

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.88 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

THC vs. VTRS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

THC

4.36

Health Care Providers & Services Industry

Max
7.61
Q3
4.32
Median
2.53
Q1
1.14
Min
0.77

THC’s P/B Ratio of 4.36 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

VTRS

0.67

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

THC vs. VTRS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolTHCVTRS
Price-to-Earnings Ratio (TTM)10.79--
Price-to-Sales Ratio (TTM)0.770.88
Price-to-Book Ratio (MRQ)4.360.67
Price-to-Free Cash Flow Ratio (TTM)7.247.29